Please login to the form below

Not currently logged in
Email:
Password:

GSK collaborates with SuperGen

GSK has entered into a multi-year collaboration to discover and develop cancer therapeutics based on epigenetic targets with SuperGen

GlaxoSmithKline (GSK) has entered into a multi-year collaboration to discover and develop cancer therapeutics based on epigenetic targets with SuperGen, a pharmaceutical company dedicated to the discovery and development of novel cancer therapeutics in epigenetic and cell signalling modulation. 

Under the terms of the agreement, SuperGen will progress candidate compounds through to early clinical proof of concept, after which GSK will have the right to exercise an option to develop further and commercialise resulting production on a global basis.

SuperGen will receive $5m upfront, inclusive of a $3m common stock investment, priced at a premium to market. Total potential development and commercialisation milestones payable to SuperGen could exceed $375m. This is in addition to the potential for tiered royalties payable on net sales of any products.
 

26th October 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics